Zoar Limited Files Form F-4 as Impact Biomedical Business Combination Advances
Zoar Limited, the entity slated to become the public company in a proposed three-way transaction, has taken a key procedural step by registering the deal with U.S. securities regulators. The filing, disclosed Wednesday by DSS, Inc. (NYSE American: DSS), involves a Registration Statement on Form F-4 submitted to the U.S. Securities and Exchange Commission in connection with the previously announced business combination among Impact Biomedical Inc. (NYSE American: IBO), Zoar Limited, and certain related parties.
Form F-4 registrations are the standard mechanism for registering securities issued in cross-border business combinations, allowing shares of the combined entity to be offered to U.S. investors. The submission moves the transaction from announcement into the regulatory review phase, though it does not guarantee completion. Registration statements of this type are typically subject to SEC comments and one or more amendments before becoming effective, after which shareholder approvals and closing conditions generally remain.
DSS, Inc., headquartered in Rochester, New York, serves as an anchor of the transaction structure through its relationship with Impact Biomedical, whose shares trade on the NYSE American exchange under the ticker IBO. Upon completion of the business combination, Zoar Limited is expected to act as the public parent company, referred to in the filing as “PubCo.”
Neither the company’s announcement nor the filing disclosed an expected closing timeline, transaction valuation, or exchange ratio in the materials summarized here. Investors tracking the deal will likely look for subsequent amendments to the Form F-4, which typically contain detailed financial statements, pro forma combined financials, and background of the merger sections that have not yet been made public.
While this transaction sits outside the metals and mining sector, cross-listed micro-cap companies on the NYSE American often draw attention from investors screening for small-capitalization securities, a universe that also includes junior resource names such as lithium explorer LI.V, whose shares last traded at $0.47, up 0.53% on the day, with a market capitalization of roughly $120.2 million.
What to watch
- SEC review of the Form F-4, including potential comment letters and amendments that would add deal terms and combined financial details
- Effectiveness of the registration statement and scheduling of shareholder votes by the involved parties
- Any subsequent announcements from DSS, Inc. or Impact Biomedical regarding closing conditions or timing
Source: original release
